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Breast cancer is the major cause of cancer death in women in Singapore. The 
incidence of breast cancer will continue to escalate, owing to multiple factors. 
These include increased life expectancy and earlier detection, which ironically, 
arise from better nutrition, improved medical and healthcare, and national 
screening programs. The current paucity of early diagnostic markers, calls for 
a need to further understand the aetiology of breast cancer to provide better 
treatment and prevention. Breast cancer cells have been shown to exhibit the 
Warburg effect characterised by increased levels of glycolytic enzymes, 
glucose consumption and lactate production. Prion protein (PrP), a highly 
conserved cell surface glycoprotein known to cause neurodegenerative prion 
disease in human has also been implicated in cancer progression.  
 
In this project, we assessed the effect of PrP in breast cancer cells using two 
PrP over-expressing cell lines, namely human PrP MCF7 clone A 
(HuPrP/MCF7 clone A) and HuPrP/MCF7 clone B, in order to ratify our 
hypothesis. We found that increased PrP expression was associated with 
reduced proliferation rate both in a variety of breast cancer cell lines and in 
PrP over-expressing MCF7 cells. Our results, while preliminary, showed that 
PrP is associated with phosphorylated Akt at serine 473 reducing glucose 
transporter 4 (GLUT4) expression, resulting in increased lactate production. 
We speculate that PrP modulates breast cancer metabolism and is likely to be 
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1.1. A review of the role of prion protein  
 
Prion is an acronym for proteinaceous infectious particle (Prusiner, 1982). 
Prion diseases, also known as transmissible spongiform encephalopathies 
(TSEs) (Sy et al., 2002), are a group of animal and human neurodegenerative 
disorders that are invariably fatal. They are often characterized by a long 
incubation period resulting in neuronal loss, spongiform changes and 
astrogliosis (Belay, 1999). Some examples of TSEs include CJD, Gerstmann-
Straussler-Scheinker syndrome, fatal familial insomnia, kuru and many more 
(McNally et al., 2009). Prion diseases are infectious from exogenous sources, 
sporadic and/or genetic where the gene encoding the PrP is mutated (Prusiner, 
1998). The mechanism of how prion causes brain damage is poorly understood. 
It was hypothesized that the key event underlying the development of prion 
disease is the post-translational conversion of normal cellular PrP (PrPC), a 
cell surface glycoprotein, into its pathogenic isoform, the scrapie prion (PrPSc) 
(Prusiner et al., 1998, Tuite and Serio, 2010) leading to progressive neuronal 
accumulation of the latter. This in turn causes irreversible damage to the 
neurons and reduces the availability of PrPC which may interfere with the 
presumed neuroprotective role of the protein, thus resulting in the underlying 




Prion diseases have received the limelight following an outbreak of bovine 
spongiform encephalopathy (BSE) infecting several cattle in Europe and 
scientific evidence implicating foodborne transmission of BSE to humans 
resulting in a lethal disease called variant CJD (Will et al., 1996). Although 
much is known of the role of PrP in disease processes, the normal function of 
PrP remains unclear. 
 
Our research laboratory has extensive experience working on prion diseases 
(Wong et al., 2001a, Wong et al., 2001b, Wong et al., 2001c). With the recent 
research emphasis on PrP and its role in cancer, we decided to divest our 
efforts into this area as well. Before we proceed further, it is perhaps pertinent 
that we first look at the normal functions and current understanding of PrP in 
both normal, as well as in cancer development. Unless otherwise stated, the 
term ‘PrP’ as used in this thesis denotes the normal cellular form PrPC.  
 
1.1.1. Functional characteristics of PrP 
 
PrP is encoded by the highly conserved PRNP gene, consisting of two or three 
exons depending on the species. In humans, the PRNP gene has two exons 
with the entire open reading frame located in a single exon, localized in 
p12/p13 region of chromosome 20 (Basler et al., 1986). PrP is expressed in 
many organs such as the lung, heart, kidneys, gastrointestinal tract, muscle, 
and mammary glands, with the highest expression found in the central nervous 
system (Stahl et al., 1987, Brown et al., 1990, Bendheim et al., 1992). 
Although both the PrPc and PrPsc share the same primary structures, the 
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former is rich in α-helical secondary structures (Riek et al., 1997, Knaus et al., 
2001), soluble in mild detergents (Meyer et al., 1986), exists in a stable 
monomeric state, and is sensitive to proteinase-K degradation (Stohr et al., 
2008, Prusiner et al., 1983). Table 1 shows the comparison between the 
biochemical and biophysical characteristics of PrPc and PrPsc. 
 
Table 1: Biochemical and biophysical properties of PrPc and PrPsc. (Table 
modified from (Govaerts et al., 2004). 
 
PrPC PrPSc 
Non infectious Infectious 
Mainly α-helices Mainly β-sheets 
Protease K sensitive Protease K insensitive 
Does not aggregate Aggregate 
 
1.1.2. Structural aspects of PrP 
 
In humans, PrP is initially synthesized as a pre-pro-PrP of 253 amino acids in 
the cytosol. PrP contains a hydrophobic N-terminal signal peptide of 22 amino 
acids while the last 22 amino acids at the C-terminus encompass the GPI 
anchor peptide signal sequence. Cleavage of both of these sequences results in 
the mature 209 amino acid residue PrP being exported to the cell surface as an 
N-glycosylated, glycosylphosphatidylinositol-anchored protein. Nuclear 
magnetic resonance at acidic pH reveals that PrP consists of a highly-
conserved hydrophobic region (residues 106-126), a NH2-terminal flexible tail 
(residues 23-124), and a COOH-terminal globular domain (residues 125-228), 
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arranged in three monomeric α-helices, and two short β -strands flanking the 
first α -helix (Zahn et al., 2000). A single disulfide bond is found between 
cysteine residues 179 and 214. There are three sites responsible for copper 
binding which are found in the octarepeat region (residues 51-91) (Aronoff-
Spencer et al., 2000). Figure 1 shows the primary structure of PrP. 
 
Full-length human PrP consists of two N-glycosylation sites at asparagine 181 
and 197 (Haraguchi et al., 1989, Stahl et al., 1987) and can exist in three forms 
as the di-, mono-, or unglycosylated isoforms (Harris, 1999, Lehmann et al., 
1999). The functions of N-linked glycans include glycoprotein trafficking, 
structure maintenance, and may contribute to the functional properties of 






Figure 1: Picture showing primary structure of PrP. (Figure taken from 
(Ermonval et al., 2003). PrP consists of a highly-conserved hydrophobic 
region, a N-terminal region, and a C-terminal region. The latter composed of 
three monomeric α-helices, and two short β-strands flanking the first α-helix. 
A single unique disulphide bridge between the two cysteines is also found in 
the C-terminus domain. An octarepeat region encompassing the codon 51 







1.1. Physiological function of PrP 
 
While most studies are focused on the role of PrP in neurodegenerative 
diseases, its function outside the nervous system remains unclear. Some of the 
hypothesized functions of PrP include protection against apoptosis and 
oxidative stress, cellular survival, proliferation, differentiation, cellular uptake 
or binding of copper ions, transmembrane signalling, formation and 
maintenance of synapses and adhesion to the extracellular matrix (Nicolas et 
al., 2009, Westergard et al., 2007). 
 
The role of PrP in cell signalling pathways has been shown in a study where 
PrP was found to be localized in the lipid raft domains on the plasma 
membrane enriched in sphingolipids and cholesterol (Petrakis and Sklaviadis, 
2006). Further research into the signal transduction patterns suggests that PrP 
might have a role in activating various transmembrane signalling pathways 
responsible for neurite outgrowth, neuronal survival or differentiation and 
neurotoxicity (Westergard et al., 2007). Using Prnp0/0 mice, where PrP had 
been deleted, impairment of the PI3K/Akt signalling pathway upon down- 
regulation of post-ischaemic phospho-Akt expression, following post-
ischaemic Caspase-3 activation, and neuronal injury aggravation after focal 
cerebral ischaemia was shown. This thus suggested a neuroprotective role of 
PrP through regulation of the PI3K/Akt pathway (Weise et al., 2006). 
Contrariwise, the  neurotoxic effect of PrP was demonstrated to be induced via 
specific signalling cascade. Synthetic peptide PrP 106-126 which displays 
similar biochemical properties with PrPSC triggers PrPC signalling pathways 
6 
 
possibly through the JNK/c-Jun pathway where its activation is responsible for 
the PrPC mediated neurotoxicity(Carimalo et al., 2005, Pietri et al., 2006). 
 
The role of PrP in synapses was predicated upon PrP expression being up-
regulated at synapses, suggesting that it might play an important role in 
synaptic structure, function and maintenance. Kanaani et al. showed that 
exposure of cultured rat fetal hippocampal neurons to purified recombinant 
PrP resulted in rapid elaboration of axons and dendrites, and increase in 
synaptic contacts (Kanaani et al., 2005). Similarly, in another study, PrP 
facilitated synaptic transmission by inducing acetylcholine release potentiation 
at the neuromuscular junction (Re et al., 2006). Others have also shown PrP 
involvement in synapse formation and function which include reorganization 
of mossy fibre, circadian activity alterations, and cognition deficits in mice 
devoid of PrP (Colling et al., 1997, Criado et al., 2005, Tobler et al., 1996).   
 
The role of PrP in cell adhesion regulation was demonstrated in a study where 
PrP interacts with cell adhesion molecules such as neural cell-adhesion 
molecule (N-CAM). This led to the redistribution of N-CAM to lipid rafts and 
the activation of fyn kinase, an enzyme involved in N-CAM-mediated 
signalling. This process subsequently further enhanced neurite outgrowth in 
cultured hippocampal neurons (Santuccione et al., 2005). Graner et al. 
demonstrated using PC12 cells and hippocampal neurons that PrP was 
saturable, having specific and high-affinity receptors to laminin, which are 
responsible for cell proliferation, neurite outgrowth, and cellular migration 
(Graner et al., 2000). 
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1.2. Overview of cancer biology 
 
Cancer, also known as malignant neoplasm, is a type of genetic disease where 
a group of cells display uncontrolled growth (cell division beyond normal 
limits), invasion (invade and disrupt adjacent tissues), and oftentimes 
metastasis (spread to other parts of the body via the blood or lymph) (Alteri, 
2011). 
 
Cancer is the leading cause of death worldwide accounting for 7.6 million 
deaths, approximately 13% of all deaths in 2008. The top cancer deaths 
include lung, stomach, liver, colon, and breast cancer. Deaths from cancer 
worldwide are expected to continue increasing, with an estimated 13 million 
deaths in 2030 (WHO, 2012). In Singapore alone, cancer is the major cause of 
death (Singstat, 2011). As such no effort has been spared in the search for 
curative, as well as palliative treatments over the past several decades. Success 
has been limited and the field remains a vibrant and actively researched area. 
Several hallmarks of cancer contribute to these challenges encountered in 
research and are detailed in the following sections. 
 
As an example, breast cancer is a malignancy that affects breast tissue, in 
particular, the inner lining of milk ducts or the lobules that supply the duct 
with milk (Sariego, 2010). These are termed ductal and lobular respectively. 
Breast cancer is the leading cause of cancer mortality in Singaporean females 
(MOH, 2012). Amongst all the different kinds of cancer, breast cancer is 
ranked fifth highest in terms of mortality rate (WHO, 2008), while according 
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to the Singapore Cancer Registry, 1 in 17 women will develop breast cancer in 
her lifetime in Singapore. The risk of getting breast cancer increases with age, 
with the most prevalent age between 50 to 59 years in Singapore women (HPB, 
2009). 
 
1.2.1. Hallmarks of cancer 
 
How then is a cancer cell different from a normal cell? Many researchers over 
the past decades have been studying this question. They found that most, if not 
all cancers have acquired the same set of features during their development as 
they become cancerous. These hallmarks include the ability to generate self-
sustaining growth signals, insensitivity to growth-suppressor signals, 
resistance to programmed cell death (apoptosis), unlimited replication 
potential, sustained angiogenesis, tissue invasion and metastasis (Hanahan and 
Weinberg, 2000) and altered metabolism (DeBerardinis et al., 2008, Warburg, 
1956).   
 
As the cells progress to the cancerous stage, the reliance on exogenous growth 
stimulation decreases and are replaced by their own signalling which involves 
alteration of extracellular growth signals, transcellular transducers of those 
signals, or intracellular circuits that translate those signals into action 
(Hanahan and Weinberg, 2000). Platelet-derived growth factor and tumour 
growth factor alpha (TNFα) are examples of cancer cell’s growth signals in 
glioblastomas and sarcomas respectively. Cancer cells have the ability to act 
as though growth hormones are present (despite an actual absence of it), thus 
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creating a positive feedback loop known as autocrine stimulation (Heasley, 
2001). Nonetheless, cancer cells are capable of evading antigrowth signals 
possibly via modifying the components governing the transit of cells through 
the G1-phase of its proliferative cycle. This in turn allows the cancer cell to 
maintain their replicative capacities and fuel their uncontrolled growth and 
division (Hanahan and Weinberg, 2000). 
 
Apoptosis is an important process for normal development and it is a way to 
remove cells with DNA damage. Unlike normal cells, cancer cells are able to 
evade apoptosis, which result in infinite growth and division (Hanahan and 
Weinberg, 2000). p53, the tumour suppressor gene, is an important target of 
cancer. Approximately 50% of all human cancers show defects involving p53, 
resulting in functional inactivation of its product and subsequent removal of a 
key component of the DNA damage sensor that can induce the apoptotic 
effector cascade (Harris, 1996).  
 
Also, under normal circumstances, with each successive cell division, 
telomeres progressively shorten by about 50-100 bp. This eventually halts cell 
division as the telomeres become too short, hence resulting in replicative cell 
senescence (Counter et al., 1992).  Cancer cells however achieve 
immortalization and infinite replicative potential through lengthening their 
telomeres via the addition of hexanucleotide repeats by the action of 
telomerase enzyme on the ends of telomeric DNA (Bryan and Cech, 1999).    
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In order for cancer cells to sustain growth, cellular function and survival, it is 
essential for cancer cells to induce angiogenesis (formation of new blood 
vessels and sustained blood vessel growth) for oxygen and nutrient supply 
(Hanahan and Weinberg, 2000). This switch is induced by modulating the 
balance of angiogenesis inducers and countervailing inhibitors, probably 
involving gene transcription (Hanahan and Folkman, 1996). 
 
As cancer cells acquire genetic alterations making them autonomous, it gives 
them the ability to separate from the primary tumour, spreading via the 
lymphatics and blood vessels, and invading into other parts of the body to 
form secondary lesions. This ability to spread and ‘reside’ in other parts of the 
body is known as metastasis — the final stage of cancer development that 
causes 90% of human cancer deaths (Sporn, 1996).  
 
Altered metabolism is a hallmark initially described nearly a century ago, 
showing the differential aspects of cellular metabolism in cancer cells relative 
to normal differentiated cells (DeBerardinis et al., 2008, Warburg, 1956). This 
hallmark is very important for cancer cells as they need to satisfy the intense 
demands for growth and proliferation. Advancements over the past decade 
have shown that the aberrant cellular metabolism of cancer is caused by a 
combination of genetic lesions and nongenetic factors such as the tumour 
microenvironment (Hsu and Sabatini, 2008, Vander Heiden et al., 2009). 
However, there remains innumerable gaps in our knowledge of how, what, and 
where cancer cells rewire their cellular metabolism, due to the fact that cancer 
itself is a disease that is complex and heterogenous in nature. As such, a single 
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model of altered tumour metabolism will not fully encapsulate the sum of 
metabolic changes that can support cancer cell growth (Greaves and Maley, 
2012). Thus, any investigation into cancer cell metabolism will lend support to 
delineating missing pieces of the puzzle, with the grand aim of advancing 
knowledge that leads ultimately to discoveries of novel cancer treatment 
options.  
 
In the next section, I will discuss in greater depth what the altered metabolism 
in cancer cells is, how it differs from normal cells, and why this is so vital to 
cancer cell proliferation. 
 
1.2.2. The Warburg effect and its effect on cancer cell 
proliferation 
 
Generally, the cellular processes for cell proliferation and metabolism are 
closely knit (Fritz and Fajas, 2010). The metabolic programme of normal 
resting cells function to maintain homeostatic processes through adenosine 
triphoshate (ATP) production (Vander Heiden et al., 2009). In the presence of 
oxygen, most normal resting cells metabolize glucose to pyruvate through 
glycolysis, and then completely oxidize a large fraction of the generated 
pyruvate to carbon dioxide in the mitochondria through oxidative 
phosphorylation. This process yields 36 ATP from one molecule of glucose 
(Fig 2). However, in the absence of oxygen, normal cells redirect pyruvate 
away from mitochondrial oxidation or tricarboxylic acid (TCA) cycle and 




In normal proliferating cells, the metabolic programme must generate enough 
energy to support cell replication and also meet the energetic requirements for 
anabolic demands from macromolecular biosynthesis and maintenance of 
cellular redox homeostasis in response to increased production of toxic 
reactive oxygen species (ROS). ROS are produced during stressful situations 
in the cell and they are highly reactive radicals capable of causing significant 
damage to cell structures. Too much ROS in the cells cause oxidative stress, 
resulting in cells arresting in cell-cycle, and after prolonged arrest, death from 
apoptosis. This is not favourable to cells which are undergoing proliferation 
(Burhans and Heintz, 2009). However, ROS are not always deleterious: they 
act as messengers in signalling cascades involved in cell proliferation and 
differentiation. For example, ROS are produced at low concentrations during 
the interaction between growth factors and receptors. This is essential to 
activate proliferative signalling for cell division (Chiu and Dawes, 2012). Thus 
there is a need for redox homeostasis in the cell. This process is also a 
significant requirement for a growing tumour cell (Cantor and Sabatini, 2012).  
 
In contrast to normal cells, rapidly proliferating cells or cancer cells 
metabolize glucose to lactate, even in the presence of oxygen, despite the 
process being far less efficient in net ATP production per molecule of glucose 
(Fig 2) (Vander Heiden et al., 2009). Such a process is called ‘aerobic 
glycolysis’ or the Warburg effect. Although aerobic glycolysis has low 
efficiency in ATP yield per molecule of glucose, it can generate far more 
energy than oxidative phosphorylation by producing ATP at a faster rate 
(Pfeiffer et al., 2001). It was hypothesized that aerobic glycolysis or the 
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Warburg effect benefits cancer cells in several ways. Firstly, the glycolysis 
process is highly interconnected with several other metabolic pathways — 
particularly those associated with de novo synthesis of cellular building blocks 
where many glycolytic intermediates serve as substrates. This is important for 
fast cell growth as it maintains large pool sizes of glycolytic intermediates 
such as nicotinamide adenine dinucleotide phosphate  (NADPH), acetyl-coA, 
and ATP, which are needed for anabolic reactions (Hume and Weidemann, 
1979, Vander Heiden et al., 2009). Next, increased aerobic glycolysis is 
postulated to support cancer cell survival, growth and invasion by conditioning 
the tumour microenvironment (Koukourakis et al., 2006) through starving 
their neighbours. This provides cancer cells more opportunities for invasion 
and gaining of space for growth (Gillies and Gatenby, 2007). Thirdly, with 
more glycolysis more ROS will be produced to increase cell proliferation and 
survival via post-translational modification of kinases and phosphatases 
(Giannoni et al., 2005, Lee et al., 2002).  
 
The Warburg effect has been clinically exploited for diagnostic benefit 
through the use of Positron Emission Tomography (PET) with the glucose 
analogue, 2-deoxy-2-[18F] fluoro-D-glucose (FDG), as a tool for detecting and 
staging malignancies (Groves et al., 2007). However, drugs that act by 
targeting the metabolic alteration in cancer have yet to be developed — 
despite much speculation — and may be a potential therapeutic target for 
tumour tissues within cancer patients. However, there are challenges that need 
to be resolved when targeting tumour metabolism, given that normal 
proliferating cells share similar metabolic needs and adaptations (Wang and 
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Green, 2012). In addition, although the mode of metabolic alteration necessary 
to support proliferative requirements is a hallmark of cancer, a single 
conceptual model for the cancer metabolic programme does not exist. This is 
due to the biological variability across cancer types, the diversity among 
tumours of the same subtype, and the heterogeneities present even within a 
single tumour ‘clone’ (Cantor and Sabatini, 2012). Thus it is expected that 
many metabolic signatures and distinct dependencies may arise across the 
neoplastic cells.   
 
 
Figure 2: Picture showing the difference between oxidative 
phosphorylation, anaerobic glycolysis, and aerobic glycolysis (Warburg 






Accordingly, normal cells possess a variety of checkpoints to enable correct 
maintenance of the signalling and transcriptional circuitry that modulates cell 
growth, but various tumorigenic lesions impart cancer cells with the ability to 
evade proper regulation. 
 
1.2.3. PI3K/AKT signalling pathway and altered 
metabolism in cancer cells 
 
Dysregulation of oncogene signalling cascades is implicated in altered 
metabolism, apoptosis and other phenotypic features observed in cancer cells 
(DeBerardinis, 2008).  In this section, emphasis will be placed on the 
molecular mechanisms of Akt in cancer. In particular, the way Akt is involved 
in the metabolic switch to favour aerobic glycolysis (Warburg effect) in cancer 




Figure 3: Picture showing the downstream substrates of Akt and its 




Akt has pleiotropic functions and is a central player in several distinct 
pathways. Once activated, Akt can phosphorylate many intracellular targets to 
mediate several downstream signalling cascades leading to several diverse 
biological effects such as cell proliferation, survival, glucose uptake, and 
metabolism as shown in Fig 3 (Bellacosa et al., 2005; (Coffer et al., 1998, 
Lawlor and Alessi, 2001).  
  
As Akt is implicated in numerous pathways that are crucial for cancer 
development, it is obvious why Akt is a major therapeutic target for cancer 
(Bellacosa et al., 2005).  With Akt having such central yet diverse roles in 
cancer progression, we decided to begin dissecting the interconnections 
through a focus on its role in the metabolic pathway (Fig 4). Hopefully, this 










A discussion of Akt will invariably need to start from its upstream effector, 
phosphoinositide 3-kinase (PI3K). PI3K is a heterodimeric protein consisting 
of two functional subunits, the 85 kDa regulatory subunit, and a 110 kDa 
catalytic subunit. Activation of the PI3K signalling pathway is induced by pro-
survival signals such as cytokines, growth factors, hormones, and Ras 
activation. Ras binds directly to the Src homology 2 domain in the p85 
regulatory subunit. This leads to the activation of the p110 catalytic subunit 
resulting in the phosphorylation of phosphatidylinositol 4,5-bisphosphate 
(PIP2) to phosphatidylinositol (3,4,5)-triphosphate (PIP3). This process is 
inhibited by phosphatase and tensin homolog (PTEN), a tumour suppressor. 
PTEN is located on chromosome 10 and its deletion or mutation leads to 
several human cancers (Vivanco and Sawyers, 2002). PTEN works as a 
negative regulator of PI3K dephosphorylating PIP3 back to PIP2 resulting in 
the deactivation of PI3K signaling pathway.  
 
Now, an important downstream effector of the PI3K pathway is protein kinase 
B, also known as Akt. Through its pleckstrin homology domain, Akt interacts 
with PIP3 and undergoes a conformational change allowing 3-
phosphoinositide-dependent protein kinase-1 (PDK1) to phosphorylate Akt at 
threonine 308 (thr308). Mammalian target of rapamycin complex 2 (mTORC2) 
phosphorylates a second site on Akt, serine 473 (ser473) to allow maximum 





Over-activation of PI3K/Akt signalling pathway is important for cancer 
survival and progression as it contributes to the Warburg effect via several 
mechanisms. Firstly, the activation of Akt signalling pathway promotes the 
translocation of glucose transporter (GLUT4) from the cytosol to the plasma 
membrane, thus increasing glucose uptake (Whiteman et al., 2002, Lawlor and 
Alessi, 2001). Secondly, activation of Akt stimulates mitochondria-associated 
hexokinase activity, a glycolytic enzyme, promoting HKII translocation to the 
outer mitochondrial membrane and interacts with the permeability transition 
pore to promote cell survival (Gottlob et al., 2001). The stimulated hexokinase 
activity also initiates glycolysis and the pentose phosphate pathway by 
phosphorylating glucose to form glucose-6-phosphate resulting in increased 
influx of glucose into the cell along its concentration gradient (Robey and Hay, 
2006). Thirdly, activation of Akt pathway induces the expression of another 
glycolytic enzyme, phosphofructokinase, that phosphorylates fructose-6-
phosphate to fructose-1,6-bisphosphate, thus driving up glycolysis rate  
(Vander Heiden et al., 2001).  
 
1.2.4. p53 and its role in altered cancer cell metabolism  
 
Recent studies have pointed to the multifaceted role for p53 in metabolic 
control  (Gottlieb and Vousden, 2010). p53 transcription factor is one of the 
important components for protecting cells against stresses that may otherwise 
initiate tumorigenic progression. Activation of p53 offers anticancer 
mechanisms via maintainence of genomic integrity, DNA repair, cell-cycle 
arrest, and apoptosis (Vogelstein et al., 2000). This makes p53 an important 
tumour suppressor as approximately 50% of all human cancers consist of 
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mutations or deletions in the TP53 encoding gene. Baker et al. reported in their 
study that 26% of women with breast cancer harboured p53 mutations. (Baker 
et al., 2010). Since p53 has protective functions against tumorigenic 
progression, it is not surprising that p53 also directs metabolic characteristics 
consistent with those of normal resting cells, in particular, their involvement in 
glucose metabolism through regulating glycolysis and the concomitant 
stimulation of oxidative phosphorylation. The functions of p53 in metabolism 
is shown in Table 2 and further elaborated below. 
 
Table 2: Roles of p53 in metabolism. Studies that demonstrated p53 roles in 
metabolism. 
 
Roles of p53 in metabolism 
Induces synthesis of TP53-induced 
glycolysis and apoptosis regulator 
(TIGAR) expression 
Bensaad et al., 2006 
Induces synthesis of cytochrome 
oxidase 2 (SCO2) 
Matoba et al., 2006 
Involved in glucose metabolism in a 
transcription-independent manner 
Jiang et al., 2011 
Repress the transcriptional activity of 
GLUT1 and GLUT4 gene promoters 
Schwartzenberg-Bar-Yoseph et al., 
2004 
 
p53 transcriptionally induces synthesis of TIGAR expression which lowers 
fructose-2,6-bisphosphate levels in cells. This results in an inhibition of 
glycolysis (Bensaad et al., 2006). p53 also transcriptionally induces the 
synthesis of SCO2 which is needed for correct assembly of the cytochrome c 
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oxidase complex in the mitochondrial electron transport chain. This ensures 
mitochondrial respiration takes place without disruption (Matoba et al., 2006). 
 
Next, p53 may also be involved in glucose metabolism in a transcription-
independent manner via direct binding and inhibition of glucose-6-phosphate 
dehydrogenase (G6PDH) in the cytoplasm (Jiang et al., 2011). G6PDH, is 
involved in a rate-limiting step catalysing the first reaction in the diversion of 
glucose-6-phosphate to the oxidative pentose phosphate pathway (PPP). 
Consequences for G6PDH inactivation include dampening of the biosynthetic 
programmes, arising from reductions to ribose-5-phosphate (nucleoside 
biosynthesis) and NADPH (lipid biosynthesis) levels. 
 
p53 is also found to repress the transcriptional activity of GLUT1 and GLUT4 
gene promoters (Schwartzenberg-Bar-Yoseph et al., 2004). The reduction of 
GLUT1 and GLUT4 can lead to dampening of glycolysis as glucose flux into 
the cells is decreased and is thus able to inhibit the Warburg effect in cancer 
cells. 
 
In addition, compared to wild-type p53, the p53-deficient cells demonstrate 
increased glucose flux into the oxidative PPP and marked elevation of 
NADPH levels and lipogenic rates (Jiang et al., 2011).   
 
Therefore, the above points show that p53 plays a major role in the 
metabolism of cells. Apart from these, it was reported that p53 directly 
regulates the transcription of PrPC (Vincent et al., 2009) but its role in 
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metabolism, particularly cancer metabolism, is not known. So it is of great 
interest to investigate the relationships, if any, between prion, p53 and Akt in 
cancer metabolism. 
 
1.3. The Role of PrP in cancer biology 
 
Although PrP is known to be highly expressed in the nervous system, this 
protein has been detected in various other systems throughout the body such as 
lymphoid cells, lung, heart, kidney, gastrointestinal tract, muscle, and 
mammary glands. Since then, emerging studies have implicated PrP in cancer 
biology, involving the cells’ resistance to apoptosis, proliferation, and 
metastasis. 
 
1.3.1. PrP and apoptosis 
 
The role of PrP in anti-apoptotic activity has been studied in a range of 
experimental systems such as in mice, cultured mammalian cells, and yeast. 
However, the role of PrP remains unclear although their results suggest a 
common mechanism for its cytoprotective activity. 
 
The generation of a PrP knockout mice using homologous recombination in 
embryonic stem cells such as Prnp0/0 (Zürich I) and Prnp-/- (Edinburgh) 
display distinct neurophysiological alterations and progressive demyelination 
in the peripheral nerves (Bueler et al., 1992, Mehrpour and Codogno, 2010). 
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Following that, the development of PrP knockout mice lines such as Prnp-/- 
(Nagasaki), Rcm0, and Prnp-/- (Zürich II) displayed ataxia and age-related 
Purkinje cell loss. The reintroduction of Prnp-encoding transgene into 
Nagasaki, Zürich II, and Rcm0 PrP-null mice has been shown to reverse the 
neurodegeneration effect, suggesting a neuroprotective function of PrP (Moore 
et al., 1999, Sakaguchi et al., 1996). The use of N-terminally deleted forms of 
PrP in transgenic mice also demonstrated the neuroprotective activity of PrP. 
Following PrP deletions (∆32-121 or ∆32-134), the mice displayed severe 
ataxia and progressive neurodegeneration limited to the granular layer of the 
cerebellum as early as 1-3 months after birth. The introduction of single copy 
wild-type PrP gene completely abolishes the defect (Shmerling et al., 1998).   
 
Utilising human primary neurons, PrP (having the intact octarepeat region) 
was found to inhibit Bax (Bcl-2 associated X protein)-mediated neuronal 
apoptosis in spite of the GPI anchor signal peptide truncation (Bounhar et al., 
2001). It was therefore hypothesized that the octarepeat region of PrP is 
important for the anti-Bax function since the domain displays similarity with 
the BH2 domain of B-cell lymphoma (Bcl-2) which is required for inhibition 
of apoptosis. In another study, familial PrP mutations D178N and T183A 
associated with the human prion diseases has been shown to partially or 
completely abolish the neuroprotective function of PrP against Bax (Roucou 
and LeBlanc, 2005). Using co-expression of various Syrian hamster PrP 
mutants in MCF-7 cells and primary human neurons, it was found that the PrP 
in the cytosol is responsible for the Bax inhibition activity (Lin et al., 2008, 
Roucou et al., 2003). However, the physiological importance of cytosolic PrP 
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remains uncertain as in vivo generation of this form of PrP from the wild-type 
molecule appears to be modest (Stewart and Harris, 2003). 
 
Studies indicate that the cytoprotective effect of PrP is very specific for Bax. 
Nevertheless, it was proposed that PrP does not interact directly with Bax to 
prevent cell death but rather, works with Bcl-2 to maintain the inactive state of 
Bax and thence grant neuroprotection in mammalian cells (Roucou et al., 2005, 
Roucou and LeBlanc, 2005). Notwithstanding, it currently remains 
inconclusive whether PrP really has its role in Bax to confer neuroprotection. 
This is because in a yeast study (S.cerevisiae), a form of mouse PrP 
encompassing a charged region of residue 23-31 and containing a modified 
signal peptide has been shown to dampen cell death in yeast expressing 
mammalian Bax from a galactose-inducible promoter despite the deletion of 
the octapeptide repeat region (Li and Harris, 2005, Westergard et al., 2007). In 
addition, in the Bax-expressing yeast study, cytosolic PrP (23-231) failed to 
demonstrate a rescue effect in growth, suggesting that the anti-apoptotic 
activity requires targeting of PrP to destinations of the secretory pathway (Li 
and Harris, 2005, Westergard et al., 2007). Therefore, the anti-apoptotic effect 
of PrP in yeast appears to be dependent on its interactions with endogenous 
yeast proteins downstream of Bax during cellular stress (Li and Harris, 2005).  
 
In contrast to these studies, using cultured hippocampal neurons, primary 
cultures of mouse cerebral endothelial cells expressing PrP and retina, the 
hydrophobic, amyloid PrP fragment 106-126 has been shown to increase 
toxicity (Deli et al., 2000, Ettaiche et al., 2000). Extending these studies, PrP 
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fragment 106-126 exposure to primary culture of murine cortical neurons and 
transgenic mice 338 cortical neurons has resulted in neuronal death within 24 
hours which might be due to activation of c-Jun-N-terminal kinase (Crozet et 
al., 2008). Overexpression of PrP in human embryonic kidney 293 cell lines, 
rabbit epithelial Rov9 cell lines, and murine cortical TSM1 cell line resulted in 
cells sensitive to the apoptotic inducer, stauroporine, a response involving 
Caspase-3 activation via transcriptional and post-transcriptional control of p53 
(Paitel et al., 2003, Paitel et al., 2004) 
 
1.3.2. PrP and cancer biology 
 
Supporting studies have shown plausible implications of the role of PrP in 
cancer biology. PrP has been found to be required for the proliferation of 
enterocytes and this could be due to its interaction with desmoglein and c-Src, 
observed using co-immunoprecipitation experiments (Morel et al., 2008). c-
Src is a tyrosine kinase and its activation promotes cellular proliferation and 
survival (Marcotte et al., 2012) thus suggesting that PrP might be involved in 
the activation of c-Src to induce cell proliferation.  
 
Given that PrP is needed for cell proliferation in enterocytes, it is not 
surprising that PrP has also been shown to play a role in colon cancer. PrP 
neutralising antibodies have been shown to suppress tumour growth in 
HCT116, a human colon cancer cell line model (McEwan et al., 2009). 
PrP has also been found to be essential in ensuring cell survival after cells 
receive apoptotic signals (Ponder, 2001, Kumar et al., 2004, Makin and Dive, 
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2001). Overexpression of PrP has been shown to prevent tumour necrosis 
factor alpha (TNF-α)-induced apoptosis in MCF7 cells. The exact mechanism 
is unknown but PrP is able to prevent cytochrome c release from mitochondria 
and nuclear condensation (Diarra-Mehrpour et al., 2004). Subsequent studies 
show that silencing of PrP expression in human breast adenocarcinoma TNF-
related apoptosis inducing ligand (TRAIL) sensitive MCF7 cell line and its 
two resistant counterparts, the multidrug resistant MCF7/ADR and TRAIL-
resistant clones, have been shown to mediate Bax activation upon down-
regulation of Bcl-2 expression. This in turn sensitizes breast cancer cells to 
TRAIL-induced apoptosis associated with caspase processing, Bid cleavage 
and MCL-1 degradation (Clohessy et al., 2006, Mehrpour and Codogno, 2010). 
Subsequent studies using siRNA to knockdown PrPc expression in gastric 
cancer MKN28 cells resulted in the cells becoming sensitive to hypoxia-
induced drug sensitivity (Liang et al., 2007). 
 
PrP has also been shown to promote cancer metastasis and invasiveness. Pan 
et al. showed that PrPc expression in gastric cancer lines SGC7901 and 
MKN45 significantly promotes adhesive, invasive, and in vivo metastatic 
capabilities of the cells in conjunction with increased promoter activity and 
up-regulation of matrix metalloproteinase-11 (MMP11) expression, a protease 
which is needed for cancer cell invasion. The N-terminal fragment of PrPc was 
implicated to promote invasion and metastasis at least in part of the 
MEK/ERK pathway activation and subsequent MMP11 transactivition upon 
activity of ERK1/2 phosphorylation (Pan et al., 2006). In another study PrPc 
over-expression was demonstrated to promote carcinogenesis, G1/S-phase 
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transition, and proliferation in SGC7901  and AGS gastric cancer cells at least 
in part via mediating the PI3K/Akt pathway activation and subsequent 
CyclinD1 transactivation, in which the octapeptide repeat region might play an 
obligatory role (Liang et al., 2007).   
 
As PrP has been shown to affect multiple aspects of cancer development, it 
has been suggested that PrP might serve as a biomarker for cancer 
aggressiveness. The incompletely processed form of PrP, the pro-prion, could 
be used as a biomarker for pancreatic cancer because a subpopulation of 
pancreatic cancer patients with pro-prion displays shorter survival than 
patients without it (Li et al., 2009a).  
 
1.3.3. PrP and breast cancer biology 
 
The contribution of PrP to breast cancer biology has been shown by several 
studies (Li et al., 2009b, Li et al., 2011, Liang et al., 2009, Meslin et al., 2007b, 
Roucou et al., 2005, Yu et al., 2012).  The role of PrP in MCF7 in inhibiting 
TNF (Diarra-Mehrpour et al., 2004) or Bax induced cell death (Roucou et al., 
2005) was explained in the previous section.  
 
Studies by Meslin et al. have demonstrated that the expression of PrPc is 
associated with adjuvant chemotherapy resistance in patients with estrogen 
receptor (ER)-negative breast cancer, where 15%  patients displayed positive 
PrPc expression in primary breast cancer tissue. Therefore, tumours expressing 




Silencing of PrP expression in adriamycin-resistant MCF7 (MCF7/Adr cells) 
was reported to sensitise the cells to TRAIL inducing cell death (Meslin et al., 
2007b). More recently, an opposing study indicated that PrP knockdown in 
MDA-MB-435 breast cancer cell increased resistance of the cells to 
chemotherapeutic drug doxorubicin-induced cytotoxicity (Yu et al., 2012). 
These disparate results clearly indicate that the role of PrP in cancer biology is 
far from being clear and that further studies are definitely required to 
understand the role PrP has in breast cancer biology, for us to be able to 
elucidate the physiological function of PrP. 
 
Against this backdrop of possible roles PrP play in cancer development, it is 
perhaps helpful for us to return to a consideration of some fundamental aspects 
of cancer biology and its signalling pathways. This way, it would provide us 
with further insights into outstanding uncertainties in the relationship between 
PrP and cancer development. 
1.4. Aims and hypothesis 
 
Since there are numerous studies demonstrating strong association between the 
metabolic pathways and other factors that regulate the hallmarks of cancer 
such as uncontrolled proliferation and resistance to apoptosis, a thorough 
investigation of the many metabolic enzymes, intermediates and products 
governing the switch of metabolic activities in cancer is crucial to expand 
possible areas for disease-modifying therapies and discovery of new 




Taken together, the reports suggest PrP has a role in increasing the 
aggressiveness of cancers. This has been shown to be mediated by the c-Src 
and MEK/ERK pathway. As discussed in section 1.2.3 and 1.2.4, Akt 
activation and aerobic glycolysis also contributes to a more aggressive cancer 
phenotype. However the link between PrP, p53, Akt activation and aerobic 
glycolysis has never been investigated 
 
As such, we hypothesize that PrP might activate Akt which in turn leads to 
increased proliferation and the metabolic switch from oxidative 
phosphorylation to aerobic glycolysis. Given that breast cancer is the most 
common form of cancer in women in Singapore, we chose to base our studies 
on breast cancer tissues and cells, to address our hypothesis. This will then 
lead on to the finding of early markers for therapeutic intervention that has 
disease modifying effect, in hope of bringing down death due to breast cancer.  
 
In addition, the contribution of PrP to breast cancer biology has been shown 
by various studies, yet the role of PrP is still unclear. Thus far, it remains 
unclear what role PrP has in breast cancer metabolism.    
 
In this study, we will use (a) normal breast tissue vs breast cancer tissue, (b) 
normal breast cell line vs breast cancer cell lines, and (c) breast cancer cell line 
clones overexpressing PrP. 
 
Hence the aim of our study is to investigate: 
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1) If PrP is differentially expressed in: 
a. Normal breast tissue vs breast cancer tissue 
b. Normal breast cancer cell line vs breast cancer cell lines 
2) Differences, if any, between (1a) and (1b) in terms of: 
a. p53 
b. Akt 
c. Surrogate markers for metabolic activity, i.e. pyruvate, LDH-A, 
lactate production, and/or glucose transporters 











Avian myeloblastosis virus reverse transcriptase (AMV RT), deoxynucleotide 
triphosphates (dNTPs), Oligo(dT) primer and CytoTox 96 Non-radioactive 
Cytotoxicity Assay kit were purchased from Promega (Madison, WI, USA). 
Radioimmunoprecipitation assay (RIPA) buffer, anti-p53 (Cat# 9282), anti-
Akt (pan) (Cat# 4691), anti phospho-Akt (ser473) (Cat# 9271), anti phospho-
Akt (thr308) (Cat# 9275), and anti-Glut4 (Cat# 2299) were purchased from 
Cell Signaling Technology (Danvers, MA, USA). Anti PrP 8H4 was from 
Case Western Reserve University. Anti-Glut1 (Cat# 07-1401), Horse Radish 
Peroxidase (HRP)-conjugated goat anti-mouse IgG (Cat# AP181p), and HRP-
conjugated goat anti-rabbit IgG (Cat# AP187p) were purchase from Millipore 
(USA). Rabbit anti-beta actin (Cat# A2066), mouse anti-beta actin (Cat# 
A5316), cholera toxin, and ponceau S were purchased from Sigma-Aldrich 
(USA). Phosphatase inhibitor cocktail, PhosSTOP, and protease inhibitor 
cocktail, and cell proliferation ELIZA, BrdU were purchased from Roche 
(Basel, Switzerland).  
 
Fetal Bovine Serum (FBS), Dulbeccos Modified Eagles Medium (DMEM), 
sodium pyruvate, horse serum, human epidermal growth factor (hEGF), and 
One Shot TOP10 E. Coli, TRIzol, Taqman probes, pENTR™ Directional 
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TOPO® Cloning Kit , pcDNA6.2/V5-DEST, LR clonase, and blasticidin S 
were purchased from Invitrogen (Eugene, OR, USA).  
 
Bicinchoninic acid (BCA) protein assay kit was purchased from Pierce (USA). 
Nitrocellulose membrane 0.22 µm pore size, 30% acrylamide/bis 37.5:1 
solution, ammonium persulfate N,N,N',N'-tetramethylethylenediamine 
(TEMED), 0.5 M Tris-HCl pH 6.8, 1.5 M Tris-HCl, pH 8.8, and Precision 
Plus protein dual color standards were purchased from Bio-Rad (Hercules, 
CA, USA). Gels were cast according to instructions from Bio-Rad (Hercules, 
CA, USA) and used within 3 days of casting. 
 
Phosphate buffered saline (PBS) was prepared from 10X concentrated 
solutions purchased from 1st Base Asia (Singapore). Molecular biology grade 
agarose, and sodium dodecyl sulfate (SDS) were also purchased from the same 
company. 
 
RNeasy Mini kit, and Plasmid Midi Kits were purchased from Qiagen (Hilden, 
Germany). Luria-Bertani (LB) broth was purchased from BD Dilfco (NJ, 
USA).  
For cell cloning, we used Amaxa® Cell Line Optimization Nucleofector® Kit 
which was purchased from Lonza (Germany). The lactate assay and pyruvate 







2.2. Cell culture/cell lines  
 
MCF10A cell line was a generous gift from Dr. Lih Wen Deng, Department of 
Biochemistry, National University of Singapore (NUS). MCF7, SK-BR-3, and 
MDA-MB-231 cell lines were generous gifts from Prof. H. Phillip Koeffler, 
Department of Medicine, Yong Loo Lin School of Medicine, NUS. MCF10A 
cells are cultured in DMEM with 10% horse serum, 100 ng/mL cholera toxin, 
10 µg/mL hEGF, and 0.5 mg/mL hydrocortisone. The rest of the cell lines 
used in this study were cultured in DMEM supplemented with 10% FBS, with 
sodium pyruvate. All cell lines were subsequently maintained at 37°C in a 
humidified incubator supplied with 5% CO2. 
 
2.2.1. MCF10A (CRL-10317TM) 
 
MCF10A cells are immortalized, non-transformed epithelial cell line derived 
from human fibrocystic mammary tissue. They are defined as “normal” breast 
epithelial cells because they have a near diploid karyotype and are dependent 
on exogenous growth factors for proliferation. Studies have shown that they 
do not have the ability to form tumours in nude mice and are unable to grow in 







2.2.2. MCF7 (HTB-22) 
 
MCF7 cells are immortalized, adherent epithelial cells derived from human 
adenocarcinoma mammary tissue. They are estrogen receptor (ER) positive 
cell lines having hypertriploidy to hypotetraploidy karyotype.  
 
2.2.3. SK-BR-3 (HTB-30) 
 
SK-BR-3 cells are immortalized, adherent epithelial cells derived from human 
breast adenocarinoma. They are ER negative near triploid cell line. 
 
2.2.4. MDA-MB-231 (HTB-26) 
 
MDA-MB-231 cells are immortalized, adherent epithelial cells derived from 
human breast adenocarinoma. They are ER negative near triploid cell line. 
 
2.3. Quantitative real-time PCR analysis 
 
2.3.1. Isolation of total RNA 
 
RNA extraction for all cell lines was done using TRIzol reagent. A confluent 
T-25 flask (Nunc) of cultured cells was used. Cells were scraped and harvested 
in 1X PBS, which was followed by a centrifugation step to yield a cell pellet. 
This is followed by adding 500 µL of Trizol reagent. To ensure thorough lysis 
of cell pellet, the lysate was homogenized by 20 passages through a 22G 
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needles. The lysate was then processed following manufacturer’s instructions 
provided in the material datasheet up to the RNA precipitation stage. The 
precipitated RNA fraction was then subjected to an additional clean-up step 
using the RNeasy Mini kit. RNA samples were typically eluted twice in 40 µL 
of RNase free water provided in the kit. Consequently, Nanodrop™ 2000 was 
utilized for determination of the purity and concentration of RNA. 
 
2.3.2. Reverse transcription of RNA 
 
Typically, 1 µg of total RNA extracted was adjusted to a total volume of 11 
µL with sterile Milli-QTM water and then heated at 70 °C for 10 mins and 
placed on ice before master-mix containing the AMV reverse transcriptase 
was added. The master-mix consists of 4 µL 5X reverse transcription buffer, 2 
µL 10 mM dNTP mixture, and 1.5 µL oligo(dT)15 Primer. The resulting 
mixture was then incubated at 42°C for 20 mins to allow for cDNA synthesis. 
Lastly, the cDNA was heated at 95°C for 5 mins and placed on ice for another 
5 mins to inactivate the reverse transcriptase enzyme. The complementary 
deoxyribonucleic acid (cDNA) is now ready to use for quantitative RT-PCR. 
 
2.3.3. Quantitative real-time PCR 
 
Each real-time PCR reaction was performed using 200 ng of cDNA. Samples 
were ran in duplicates in volumes of 20 µL each. Specific TaqMan probes 
were used for the detection of various gene products. A typical reaction setup 
consists of the following components: 
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Table 3: PCR reaction mix  
  
Component Volume (µL) Volume (µL) 
2× TaqMan® Gene Expression Master Mix  10 
20× TaqMan® probe  1 
Nuclease free water  7 
cDNA  200 ng 
Total volume  20 
 
 
Reactions were then run in a 96-well format on a StepOnePlus™ Real-time 
PCR system (Life Technologies, Carlsbad, California USA) using the default 
cycling conditions. For each real-time PCR, a minimum of n=3 sets of samples 
were used and each sample ran in duplicates to ensure accuracy. Statistical 
analysis of the results was done using the Student’s t-test. 
 
2.3.4. TaqMan® probes  
 
The expression levels of the following genes were investigated using 
quantitative real-time PCR and TaqMan probe-based chemistry (Life 
Technologies, Carlsbad, California USA); Human actin (Hs99999903_m1), 
and human PrP (Hs00175591_m1). These probes span the exon(s) of the 









2.4. Western blotting 
 
2.4.1. Cell lysis 
 
Cells for western blot analysis were cultured in T75 flasks. Cells are harvested 
at approximately 80% confluency. Briefly, the complete media was removed 
from the flask and was rinsed with 1X PBS twice to remove excess media. The 
cells were then mechanically scraped using a cell scraper (SPL Life Sciences, 
Korea). Cells were collected in ice-cold PBS and centrifuged at 600 g for 5 
mins to obtain a cell pellet. Subsequently, the cell pellet is resuspended in 1X 
RIPA buffer. 1X RIPA buffer was prepared by adding one tablet of Complete 
Mini protease inhibitor tablet and one tablet of PhosSTOP phosphatase 
inhibitor cocktail tablet and topped up to 10 mL. The suspended pellet was 
then subjected to sonication for 3 mins to ensure thorough lysis. The resulting 
lysate was then incubated on ice for 30 mins. Finally, lysates were centrifuged 
at 14,000 g for 10 mins at 4°C to collect the supernatant. Lysates were stored 
as aliquots in –80°C prior to use. 
 
2.4.2. Tissue lysis 
 
The human breast tissues were from NUH-NUS tissue repository. All breast 
tumour tissue samples were invasive ductal carcinoma (grade 3) while normal 
breast tissues were from the same donor. Invasive ductal carcinoma is the most 




Breast tissues were weighed using an electronic balance and 1X RIPA buffer 
was added at 20% (w/v) ratio. The tissues were homogenized using a 
PowerGen homogenizer (ThermoFisher Scientific, Waltham, USA) on ice and 
then sonicated on ice for 3 times at 10 seconds each, until cells were 
completely disrupted. The homogenate was then centrifuged at 14,000 g for 30 
mins at 4°C. The supernatant was collected in aliquots and stored at –80°C. 
 
2.4.3. SDS PAGE and western blotting 
 
The protein concentration of the samples and protein standards were processed 
by diluting with assay reagent and assayed with BCA protein assay. 
Absorbance was read at 562 nm after 30 mins of incubation at 37 °C. 
Background absorbance was substracted from readings of all standards, 
controls and samples, including the no-protein control. The values for the 
protein standards were plotted with a linear regression line through the 
standard points. The protein concentrations of the samples were then 
calculated from the equation of the absorbance-concentration relationship, 
followed by multiplying with the dilution factor. Lysates were added to a 4X 
loading buffer, and boiled at 95°C for 5 mins. Samples were loaded, 
electrophoresed on 5% stacking gel at 70 V and either 7.5% or 10% SDS-
PAGE gel at 100 V for 1 to 2 hrs using Mini-PROTEAN Tetra electrophoresis 
system (Bio-Rad Laboratories, Hercules, California USA). The Precision Plus 
protein standard dual colour was used as a molecular weight standard and ran 





Figure 5: A representative standard curve with six points for protein 
quantification by BCA protein assay. The thick line is linear regression for 
the entire set of standard points. Dashed line represents interpolations for a test 
sample having absorbance 0.6. 
 
Proteins were transferred to a 0.22 µm nitrocellulose membrane using Mini 
Trans-Blot cell for 2 hours at 100 V. The blot transfer efficiency is verified 
using Ponceau S staining. 
 
The membrane was washed with PBS with 0.1% Tween-20 (PBST) twice for 
5 mins each to remove the Ponceau S stain before being blocked with 5% (w/v) 
non-fat milk in PBST for 30 mins at room temperature (RT) with gentle 
agitation using the orbital shaker and then incubated with the appropriate 
primary antibody (Table 5) overnight at 4°C with constant gentle agitation 
using an orbital shaker. Following that, the membrane was washed with PBST 
3 times for 5 minutes each before incubation with the appropriate HRP 
conjugated secondary antibody dissolved in 3% non-fat milk in PBST for 1 
hour at RT with gentle agitation with orbital shaker. The membrane was then 
washed again 3 times for 5 mins each with PBST. The bands were developed 
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using chemiluminescence. For this study, two substrates were employed for 
chemiluminescence detection on the blot. SuperSignal West Dura substrate 
was used or SuperSignal West Femto substrate as appropriate. All the blots 
were developed using KODAK Image Station 4000R (Carestream Health Inc, 
New York, USA). 
 
The membrane was stripped using Restore Western Blot Stripping Buffer for 
20 mins at RT, then washed with 1X PBST 3 times for 5 mins each, followed 
by blocking membrane with low-fat milk. Subsequently, the next target was 
examined via incubating the blot with another primary antibody following the 
same protocol used above. After the development of the bands, stripping 
method was repeated until all target used in this study was analysed. Typically, 
the blot is stripped for a maximum of two times.  
 
Table 4: Antibodies for Western blotting analysis 
 
Antibodies Source Dilution 
anti-PrP 8H4 Mouse 1:1,000 
anti-p53 Rabbit 1:5,000 
anti-Akt (pan) Rabbit 1:2,000 
anti-phosphoAkt (ser473) Rabbit 1:1,000 
anti-phosphoAkt (thr 308) Rabbit 1:1,000 
anti-Glut-1 Rabbit 1:1,000 
anti-Glut4 Rabbit 1:1,000 
anti-beta actin Rabbit 1:5,000 
anti-beta actin Mouse 1:5,000 
HRP-conjugated goat anti-mouse IgG  1:10,000 







2.5. Molecular cloning 
 
2.5.1. Gateway cloning 
 
The cDNA of PRNP was purchased from Origene. Blunt end polymerase 
chain reaction (PCR) products were produced using PCR primers designed by 
the author for specificity to human cellular PrP. The PCR primers used were 
5’-CACCATGGCGAACCTTGGC-3’ (forward) and  
5’-TCCTCATCCCACTATCAGGAAGATGAG-3’ (reverse). Basic Local 
Alignment Search Tool (BLAST) from National Centre for Biotechnology 
Information (NCB1, MD) was used to ensure that the chosen sequences were 
specific, and target sequences were aligned to the human genome database. 
 
Full length human PrP (accession no. BC012844) cDNA was amplified via 
PCR at the following condition as shown in Table 5. Subsequently, the PCR 
product is cloned into pENTR™/D-TOPO vector following standard 
procedures provided in the pENTR™ Directional TOPO® Cloning Kit. 
 






Initial denaturation 95 5 min 1 
Denaturation  95 30 sec  
 
25 Annealing 53 30 sec 
Extension 72 1 min 
Final extension 72 7 min 1 




Following transformation using One Shot® TOP10 Escherichia coli, positive 
clones were selected using 100 µg/mL kanamycin agar plates and scaled up in 
LB broth for isolation of plasmid DNA using QIAGEN Plasmid Midi Kits. 
The presence of the gene insert was confirmed by PCR analysis using the 
designed primers as mentioned above. The verified plasmids via sequencing 
were retained and used for subsequent LR cloning reactions. 
 
2.5.2. LR cloning 
 
LR cloning was subsequently performed to transfer the PRNP gene insert from 
the pENTR™/D-TOPO vector into the pcDNA6.2/V5-DEST expression 
vector via an LR recombination reaction. The LR Clonase™ II enzyme mix 
was used and the recombination reaction was performed following instructions 
in the protocol provided. Positive clones were selected using 100 µg/mL 
carbenicillin agar plates and screened using colony PCR, before they were 
scaled up in LB broth for isolation of plasmid DNA. Plasmids were then 
sequence verified using T7 forward and V5 reverse primer. Once the correct 
positive clone of interest was obtained, it was transformed into One Shot® 
TOP10 E. coli and plasmid purification was carried out using QIAGEN 
Plasmid Midi Kits. Stock of plasmid DNA was stored at –80°C for future 
purposes. The empty vector, pcDNATM 6.2 was used as a negative control 





2.6. Cell transfection 
 
2.6.1. Dose response curve of MCF7 cells 
 
Prior to transfection, a dose response was performed to determine the optimum 
concentration of blasticidin S that could kill all non-transfected cells within a 
week. To simulate conditions similar to transfection, cells were kept in 
antibiotic- and serum-free media for 24 hours overnight and allowed to 
recover for 6 h in normal DMEM before blasticidin S was added. The 
selection media containing blasticidin S was prepared from a 10 mg/mL stock 
of blasticidin S diluted in DMEM. 
 
Concentrations of blasticidin S used were: 3 µg/mL, 5 µg/mL, 7 µg/mL and 10 
µg/mL. Culture media was changed once every 3 days and the extent of cell 
death was visually inspected on an inverted microscope. The optimum 
concentration of blasticidin S for selection of stable cell clone was at 7 µg/mL 
because there was 100% cell mortality rate within a week of culture. Higher 
concentrations of blasticidin S were not suitable as they killed the cells at a 








2.6.2. Stable transfection of cell lines using nucleofection 
 
MCF7 cells were seeded into T75 flasks and maintained at 37°C in a 
humidified incubator supplied with 5% CO2 until 80% confluency. Prior to 
transfection, culture media from the cells was removed and washed once with 
PBS and harvested by trypsinization. The reaction was stopped by adding 
DMEM containing FBS and cells were centrifuged (800 rpm, 10 min, 4°C). 
After counting, the required number of cells (1 x 106 cells per sample) was 
centrifuged at 200 g for 10 min at 4°C. The pellet was resuspended in 100 µL 
of Nucleofector solution (room temperature) with 1 µg of the relevant plasmid 
DNA added. The sample was transferred into an Amaxa cuvette, which was 
inserted into the cuvette holder and the appropriate programme (P-020 for high 
transfection efficiency) was started. Both PrP DNA containing plasmid and 
empty plasmid were subjected to nucleofection while the latter served as a 
mock control. Then, 500 µL of pre-warmed culture medium was added and the 
sample was transferred into plates, which were pre-incubated with medium. 
The samples were then gently transferred into 6-well plates and put back to the 
humidified incubator at 37°C supplied with 5% CO2. Sixteen hours later, 
media containing the transfection mixture was removed and substituted with 
normal DMEM. The cells were then returned to the incubator and allowed to 
recover for 6 h before selecting for positively-transfected clones via the 





2.6.3. Selection of transfected cell clones 
 
DMEM containing 7 µg/mL of blasticidin S was added to the cells and 
selection of stable cell clones was done for a week. Subsequently cells that 
survived the antibiotic selection were trypsinized and plated column-wise at 
serial dilutions of 2-fold each in 96-well microplates, starting from a 
concentration of 50 cells per well in column 1 and by columns 6–8, it would 
end up with 1 cell per well. The cells were then cultured in maintenance media 
containing 5 µg/mL blasticidin S in DMEM and the presence of isolated cell 
colonies were determined through visual inspection on a microscope. Cell 
colonies were allowed to grow for approximately 2 weeks in microwells 
before they were trypsinized and further cultured in 24-well plates. Once the 
cells reached 100% confluency, they were trypsinized and maintained in T-25 
flasks. Half the contents of a confluent T-25 flask were cryopreserved and 
stored at –150°C. The remaining half was scaled up for screening of protein 
expression using western blotting.  
 
2.7.   BrdU assay 
 
Proliferation rate was examined using BrdU assay. All solutions mentioned 
were from the bromodeoxyuridine BrdU ELISA kit. Cells (5 x 103/well) were 
seeded onto 96-well plate. The following day, the medium was removed and 
replaced with medium containing the BrdU labelling solution prior to fixation. 
After 18 h, the medium were removed by inverting the plate and cells were 
fixed with 200 µL fixative/denaturing solution for 30 mins. After that, the 
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fixative/denaturing solution was removed by tapping it off and 100 µL of the anti-
BrdU antibody (1:100 in antibody dilution buffer) was added to the cells for one 
hour at room temperature. Cells were washed three times with 1X wash buffer 
and 100 µL of peroxidase goat anti-mouse IgG HRP conjugate was added for 30 
mins at RT. Cells were again washed three times with washing buffer. After 
tapping dry completely, cells were incubated with 100 µL substrate solution for 
15 mins at RT in the dark. The reaction product was quantified by measuring 
the chemiluminescence using a Tecan Infinite M200 plate reader. 
 
2.8.   Lactate assay 
 
Cells were seeded in 96-well plates at 10 ×  105 cells/well. When the cells 
reached at 90% confluency, the media was changed and incubated. Culture 
media was collected at 8 hours and stored at −20°C until they were assayed 
within 3 days. Lactate production in the medium was detected using lactate 
assay kit. Briefly, lactate is oxidized by lactate dehydrogenase to generate a 
product which interacts with the probe to produce a colour. Standards for the 
assay were prepared following the manufacturer’s instructions. Fluorescence 
in the wells were then allowed to develop for 30 mins in the dark before values 
were read at excitation wavelength of 535 nm and emission wavelength of 590 
nm. All values including the sample readings and standards were subtracted 
from the no-lactate control to correct for background. The standard curve was 
plotted as shown in Fig 6 and the sample readings were applied to the standard 
curve to obtain lactate concentration. The results were normalized based on 
the amount of total protein of the cells. The total protein was extracted via 
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scraping the bottom of the 96-well plates with 7 µl of RIPA buffer to lyse the 
cells.  Then, the lysate’s protein concentration was analyzed using BCA 
protein quantification mentioned in section 2.3.3.  
 
 
Figure 6: A representation of the lactate standard curve. The line is curve 
for the entire set of standard points. Dashed line represents interpolations for a 
test sample having absorbance 0.4. 
 
2.9.   Pyruvate assay 
 
Pyruvate is an important molecule made from glucose through glycolysis. 
Pyruvate is used to provide further energy either via the Kreb’s cycle or 
broken down anaerobically to produce lactate. In our experiments, cells were 
seeded in 96-well plates at 10 ×  105 cells/well. When the cells reached 90% 
confluency, they were lyzed to analyse the pyruvate concentration in the cells 
using the pyruvate assay kit from BioVision. Standards were prepared similar 
to the lactate assay in section 2.8 above and all readings were read using 
fluorescence at Ex/Em = 535/590 nm in a black microplate. 
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2.10.   Lactate dehydrogenase activity assay 
 
Lactate dehydrogenase (LDH) is a stable cytoplasmic enzyme present in most 
cells. It is release from the cell upon damage to the plasma membrane. In our 
experiments, cells were seeded in 96-well plates at 10 × 105 cells/well. When 
the cells reached at 90% confluency, the cell culture media was removed. The 
cells were then washed twice with PBS before performing cell lysis. LDH 
activity in the cell was measured via the release of cytoplasmic content using 
CytoTox 96 Non-radioactive Cytotoxicity Assay kit from Promega. The 
reaction product was quantified by measuring the absorbance using a Tecan 
Infinite M200 plate reader. 
 
2.11.   Statistical analysis 
 
Results presented were from representative experiments and data expressed as 
mean ± standard error of the mean (SEM) of at least two independent 
experiments performed in triplicates, unless otherwise stated. Tissue data were 
analysed with Microsoft Excel 2007 (Microsoft Corp., WA) using paired two-
tail Student’s t-test. The rest of the results were analysed with analysis of 
variance (ANOVA) followed by post-hoc Dunnett’s test or Bonferroni’s test. 
The statistical analysis was performed using Graphpad PrismTM software 
version 2.0 (Graphpad Software Inc., San Diego, CA, U.S.A.). A p-value of 
less than 0.05 was considered as statistically significant, as per indicated by 




3. RESULTS  
3.1. Breast cancer tissues 
 
3.1.1. Low PrP protein expression in breast cancer 
 tissues 
 
As an initial effort to characterize the role of PrP in breast cancer, the PrP 
expression was analysed in breast cancer tissue (n = 5) and compared with 
adjacent normal breast tissues. A decreased PrP expression was observed in 
breast cancer tissue compared to the normal tissue counterpart.  
 
Figure 7: PrP expression is reduced in breast cancer tissue. (A), anti-PrP 
(8H4) immunoblot of lysates prepared from breast cancer tissue compared to 
their corresponding normal breast tissue (n=5). Equal loading of the different 
lysates was verified by anti-beta actin immunoblotting. (B), band density was 
normalized against beta actin and expressed as fold change compared to 
normal breast tissue. Results shown were average ± S.E.M. Paired-samples t-
test indicates that the differences between the normal and breast cancer tissue 
is significant. *denotes p-value < 0.05. 
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3.1.2. p53 protein expression remains unchanged in breast 
cancer tissues 
 
No statistical difference was observed in p53 level between the normal and 
breast cancer tissues. This corroborates with a recent study showing that PrP 
enhances response to doxorubicin induced cytotoxity in a p53-independent 
manner (Yu et al., 2012). 
 
 
Figure 8: p53 expression remains unchanged in breast cancer tissue. (A), 
representative blot of p53. (B), densitometry results of blots. Results expressed 
as average fold change ± S.E.M. Statistical analysis revealed no statistically 
difference between breast cancer tissue with respect to their normal breast 





3.1.3. Breast cancer tissue have increased total Akt protein 
expression but not phosphorylated Akt 
 
Next, we investigated the levels of Akt in breast cancer tissues. Akt is a central 
player in many distinct pathways and is deregulated in many cancers (Vivanco 
and Sawyers, 2002).  Studies have demonstrated correlation of high Akt 
expression with breast cancer progression (Bacus et al., 2002, Perez-Tenorio et 
al., 2002). Constitutive activation of Akt is one of the characteristics of cancer 
cells that are highly dependent on glucose utilisation for energy and 
proliferation (Robey and Hay, 2009, Tomas et al., 2012).  
 
In our study, the total Akt expression was higher in breast cancer tissue 
compared to normal breast tissue (Fig 9 A-B). However, Akt phosphorylation 
did not differ between normal and breast cancer tissue (Fig 9 C-F). 
Nonetheless, Akt expression showed sufficient difference to warrant the 















Figure 9: Breast cancer tissue is associated with increased total Akt but 
not phosphorylated Akt expression. Total lysates were prepared from breast 
cancer tissue compared to their corresponding normal breast tissue. (A, C, E) 
Western blots shown are detecting for Akt, p-Akt (ser473), and p-Akt (thr308) 
respectively. (B) Band density was normalized against beta actin and (D, F) 
were normalized against total Akt. All was expressed as old change compared 
to normal breast tissues. Results shown were average ±S.E.M. of 5 
experiments. p-values were calculated using  Paired-samples t-test. *denotes 















3.2. Breast cancer cell lines 
 
3.2.1. PrP expression is higher in normal breast cell line 
than breast cancer cell lines  
 
To extend our studies with an in vitro system, we similarly examined the 
expression of PrP in commercially available cell lines (normal and cancer): 
MCF10A, MCF7, SK-BR-3, MDA-MB-231. The PrP expression in the cancer 
cell lines were markedly reduced especially in MCF7 and SK-BR-3 when 
compared against the normal breast cell line MCF10A. Cancer cell line MDA-











Figure 10: PrP expression is higher in normal breast cell line (MCF10A) 
than breast cancer cell lines (MCF7, SK-BR-3, and MDA-MB-231). (A) 
Western blots shown are representative of 3 independent experiments which 
show similar trend. (B) Band density was normalized against beta actin and 
expressed as fold change compared to normal breast cell line. Results shown 
were average ± S.E.M. of 3 experiments. The differences between normal 
breast and breast cancer cell lines were compared using Bonferroni post hoc 











3.2.2. Low PrP expression correlates with high 
proliferation rate in breast cancer cell lines. 
 
Besides invasion and metastasis, cell proliferation is also an important aspect 
of cancer progression. PrP-overexpression in gastric cancer cell lines versus 
their wild-type counterpart has been shown to increase proliferation (Liang et 
al., 2007). However, little is known about how PrP affects proliferation in 
breast cancer. The use of cell lines allows us to investigate this proliferative 
effect, which is not ethically possible clinically. 
 
BrdU was employed to examine the proliferation rate. It was observed that the 
proliferation rate of breast cancer cell lines with low PrP expression are 
significantly increased compared to that of the normal cell line MCF10A, 
suggesting possible correlations between differential PrP expression in normal 
versus breast cancer cell proliferation.   
 
As our cell line model presented the possibility that PrP might have a role in 
modulating proliferation rate in breast cancer cells, we proceeded to 







Figure 11: Proliferation rate in breast cancer cell lines. BrdU proliferation 
assay of human breast cancer cells vs. normal breast cells. Results were 
















3.2.3. p53 expression is markedly up-regulated in breast 
cancer cell lines SK-BR-3 and MDA-MB-231 
 
Although we did not observe significant differences in p53 expression 
between normal and breast cancer tissues, we investigated if the result is 
similar in the in vitro model. We found that p53 protein expression is 
markedly increased in the breast cancer cell lines SK-BR-3 and MDA-MB-
231 when compared to normal breast cell line MCF10A. No significant 




Figure 12: Up-regulation of p53 in the breast cancer cell lines but not 
MCF7. (A) Western blot of the p53 status in breast cell lines. (B) Band 
density of p53 was normalized against beta actin and expressed as fold change 
compared to normal breast cell line, MCF10A. All blots shown were 
representatives of 3 independent experiments and densitometry results are 
mean ± S.E.M. of the 3 experiments. p-values were calculated using One way 




3.2.4. Low PrP expressing breast cancer cell lines is 
associated with high Akt and induce Akt 
phosphorylation  
 
Next, we investigated the levels of Akt in the breast cell lines to verify our 
observations in breast tissues. The level of Akt expression was higher in all 
breast cancer cell lines compared with the normal breast cell line MCF10A. A 
statistical significance was seen especially with MCF7 cancer cell line. Further 
analyses on the phosphorylation status of Akt in these cell lines were studied, 
to determine correlation, if any, with PrP expression. As shown in Fig 13D, 
only SK-BR-3 had increased phosphorylated Akt (ser473) compared to 
MCF10A. No difference was observed in other breast cancer cell lines. No 
significant difference was observed between the normal and breast cancer cell 








































































Figure 13: Low PrP expression in breast cancer cell lines is associated 
with high Akt expression and induced Akt phosphorylation. (A, C, E) 
Western blots shown are representative of 3 independent experiments which 
show similar trend. (B) Band density was normalized against beta actin while 
(D, F) were normalized against total Akt; they are expressed as fold change 
compared to normal breast cancer cell, MCF10A. Results shown were average 
± S.E.M. of 3 experiments. Test of significance between normal and breast 
cancer cells were carried out using Dunnett’s post hoc test comparing the 
breast cancer cell lines with normal breast cell line. * denotes p-value < 0.05 










3.2.5. Low PrP expression is correlated with increased 
glycolytic flux metabolites 
 
 
We then examine the level of common metabolites such as lactate, pyruvate 
and LDH-A, the enzyme responsible for converting pyruvate into lactate in the 
glycolysis pathway in the breast cancer cell lines to see the metabolic status of 
these cells in relation to PrP. 
 
LDH-A  is known to be up-regulated in cancer cells (Goldman et al., 1964). 
LDH-A activity in breast cancer cell lines SK-BR-3 and MDA-MB-231 were 
markedly increased compared with MCF10A, the normal breast cell line. No 
difference was observed in MCF7 (Fig 14A).  
 
Next, we investigated the glycolytic flux status in our breast cancer cells and 
examine if it is associated with the level of PrP. The intracellular levels of 
pyruvate and lactate production in these cells were measured. The levels of 
pyruvate were markedly reduced in cancer cells, particularly in MCF7 and 
SK-BR-3 compared with MCF10A (Fig 14B). On the other hand, lactate 
production was marked increased in all breast cancer cells compared with 
MCF10A (Fig 14C). 
 
Taken together, we show for the first time proliferative breast cancer cells 
have lower PrP expression compared with MCF10A. Total Akt was found to 
be highly expressed in breast cancer cells, this, being in line with our breast 
cancer tissue results. Extending our study to look at the metabolic status of the 
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breast cancer cells, we found that breast cancer cells have high LDH-A 
activity, low pyruvate level in cells, and high lactate output compared with 
MCF10A. A relationship was observed between PrP with p53 and 
phosphorylated Akt (ser473) in our breast cancer cell lines model. To validate 
that PrP plays a role in proliferation and metabolic status in breast cancer, we 
selected one of the breast cancer cell line (MCF7) that produces the lowest 











































Figure 14: Correlation between LDH-A activity, intracellular levels of 
pyruvate and lactate production in breast cancer cell lines. (A) The LDH-
A activity measured from the cells. (B) Intracellular pyruvate level in cells. (C) 
Lactate production from cells. Results are analyzed by One-way ANOVA and 
p-values were calculated using Dunnett’s post-hoc test. ** denotes p-value < 







3.3. Transfected cell lines 
 
3.3.1. Over-expressing PrP in MCF7 cell line 
 
To examine the effects of upregulated PrP expression in low PrP expressing 
breast cancer cells, the PRNP gene was stably transfected into MCF7 breast 
cancer cells and we have generated stable clones of MCF7 cells 
overexpressing PrP (HuPrP/MCF7) or containing vector alone as a control 
(Mock/MCF7). The MCF7 cell line was selected for this study because it is a 
widely used in vitro model of breast cancer, expresses very low PrP levels, and 
it has an intact wild-type p53. These cells were then used to investigate the 
causal relationship between PrP in cancer progression and metabolic switch. 
 
Assessment of the presence of PrP was performed using real-time reverse 
transcription polymerase chain reaction to measure the amount of PrP mRNA 
as shown in Fig 15A. PrP expression was further confirmed with Western blot 
analysis using anti-PrP mAB 8H4. We successfully generated 2 clones of 






















Figure 15: Over-expressing PrP in MCF7 breast cancer cell line. (A) 
Graphs showing the Ct value of PrP expression in PrP-expressing stable clone. 
(B) Western blots shown were representative of 3 independent experiments 
which show similar trend. (C) Band density was normalized against beta actin 
and expressed as fold change compared to vector control, Mock/MCF7. 
Results shown were average ± S.E.M. of 3 experiments. Test of significance 
between vector control and PrP-expressing stable clones were carried out 
using Dunnett’s post hoc test. ** denotes p-value < 0.01. 
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3.3.2. PrP reduces cell proliferation rate  
 
BrdU assay was employed to examine the effect of PrP on the proliferation 
rate in the transfected MCF7 cells. PrP overexpression was found to reduce 
proliferation rate in HuPrP/MCF7 clone A and B. It appears that PrP might 
confer anti-proliferative effect.  
 
 
Figure 16: Over-expressing PrP in transfected MCF7 cells reduces cell 
proliferation rate.  BrdU proliferation assay of HuPrP/MCF7 and 
Mock/MCF7 cells. Results were expressed as means ± S.E.M. One-way 








3.3.3. PrP reduces lactate production in HuPrP/MCF7 
 cells 
 
Under the Warburg effect, one of the observations is that cancer cells produce 
large amounts of lactate without fully oxidising it into CO2. Here, lactate 
production was examined in HuPrP/MCF7 cells to determine the effect of 
overexpressed PrP. Both HuPrP/MCF7 clones were found to have marked 
reduction in the lactate production compared to Mock/MCF7 (Fig 17). This 
led us to question if PrP has a role in reducing glycolytic flux and thence 




Figure 17: Over-expressing PrP in transfected MCF7 cells reduces lactate 
production. Lactate production assay of HuPrP/MCF7 cells and mock/MCF7 
were assayed at 8 h following media changed. The results are normalized with 
their protein concentration. Results were expressed as means ± S.E.M. One-





3.3.4. Overexpression of PrP reduced phospho-Akt (ser473) 
but has no effect on total Akt and phospho-Akt 
(thr307) 
 
In our breast tissue and cell line study, we found that high PrP expression is 
correlated with a low Akt expression. To verify that the relationship is causal, 
Akt expression was examined in the MCF7 cells over-expressing PrP. More 
importantly, the molecular events leading to a glycolytic phenotype in breast 
cancer are not well known (Gillies et al., 2008). Akt has been implicated in 
regulating aerobic glycolysis (Elstrom et al., 2004), so we want to investigate 
if PrP is involved. 
 
In comparison to Mock/MCF7, over-expressing PrP was not found to affect 
Akt expression (Fig.18 A-B). However, PrP over-expression significantly 
decreased Akt phosphorylation at ser473 for clone B. Akt phosphorylation at 
ser473 was also decreased in clone A but the difference was not statistically 
significant (Fig 18 C-D). No change in levels of phosphorylation was observed 
at thr307 (Fig 18 E-F). So it appears that PrP might play a role in regulating 
aerobic glycolysis via exerting its effect through activating Akt at ser473. 
More study is required to investigate if PrP affects the downstream effector of 












Figure 18: Over-expressing PrP in transfected MCF7 cells reduces p-Akt 
(ser473) but has no effect on total Akt and p-Akt (thr308). (A, C, E) 
Western blots shown are representative of 3 independent experiments. (B) 
Band density was normalized against beta actin while (D, F) were normalized 
against total Akt; they are expressed as fold change compared to Mock/MCF7. 
Results shown were average ± S.E.M. of 3 experiments. Test of significant 
between Mock/MCF7 and HuPrP/MCF7 were carried out using Bonferroni 















3.3.5. PrP does not modulate p53 expression 
 
Next, we used PrP over-expressing MCF7 cell model to verify the observation 
in breast cancer tissue. As shown, there was no change in p53 expression 
between the over-expressed PrP MCF7 cells and Mock/MCF7. Hence, the role 






Figure 19: Over-expressed PrP in MCF7 cells does not affect p53 
expression. (A) Western blot of p53 status in Mock/MCF7 and HuPrP/MCF7. 
(B) Band density of p53 was normalized against beta actin and expressed as 
fold change compared to Mock/MCF7. All blots shown were representatives 
of 3 independent experiments and densitometry results are mean ± S.E.M. of 
the 3 experiments. Statistical analysis revealed no statistically difference 
between HuPrP/MCF7 and mock/MCF7. HuPrP/MCF7 clone A (p-value = 




3.3.6. Over-expressed PrP reduced GLUT4 but not GLUT1 
expression in MCF7 cells. 
 
Over-expressing PrP significantly decreased GLUT4 for clone B. There is 
decreased GLUT4 in clone A but the difference was not statistically 
significant (Fig 20 A-B). Over-expressing PrP was not found to affect GLUT1 
expression (Fig 20 C-D). Studies have shown that Akt mediates GLUT4 
trafficking (Foran et al., 1999, Zhou et al., 2004); however, Akt is not required 
for GLUT1 trafficking in some cells such as adipocytes (Foran et al., 1999). It 











Figure 20: Over-expressing PrP in transfected MCF7 cells reduces 
GLUT4 expression but not GLUT1. (A, C) Western blots shown are 
representative of 3 independent experiments. (B, D) Band densities were 
normalized against beta actin and are expressed as fold change compared to 
Mock/MCF7. Results shown were average ± S.E.M. of 3 experiments. Test of 
significant between Mock/MCF7 and HuPrP/MCF7 were carried out using 














Cancer cells generally have altered metabolism (Warburg effect) to satisfy 
their need for proliferation and survival. Whilst genetic alterations have been 
intensively researched on in breast cancers, the corresponding metabolomics 
modulation have not been well characterized (Brauer et al., 2012). The 
expression of PrP in human breast cancer tissue was first observed by Meslin, 
F. et al., demonstrating that PrP was mainly expressed by myoepithelial cells 
in normal breast tissue using immunohistochemical staining (Meslin et al., 
2007a). Endogenous PrP expression has also been demonstrated to correlate 
with tumour grade in breast cancer cell lines (McEwan et al., 2009). As an 
initial effort to characterize the role of PrP in breast cancer, expression levels 
of PrP in normal and breast cancer tissues were examined. Using 
immunoblotting analysis on 5 sets of tissues, the expression of PrP was shown 
to be significantly lower in tumour compared to adjacent normal tissues. 
However, with a small sample size, caution is pertinent as the findings might 
not be generally applicable. Hence, we carried out the investigation of PrP 
expression in a panel of breast cancer cell lines and found that PrP was 
significantly reduced in the tumour-derived cell lines compared with normal 
breast cell MCF10A, which is in agreement with our earlier observations with 
cancer tissues. Despite a small sample size (n=5), our results were consistent 
with the in vitro breast cancer cell line model. More work is required to 
investigate the correlation of PrP expression with histological grades in breast 
cancer tissue to understand definitively the role of PrP in human tumour 




While larger tissue numbers are warranted to allow better powered analysis of 
characterizing the role of PrP in breast cancer, an important next step is to 
understand if endogenous PrP correlate with metabolic subgroups. Several 
studies indicated that PrP enhances cancer cell proliferation and plays a role in 
poor prognosis for certain cancers, proposing PrP as a contributing factor in 
cancer biology (Li et al., 2009a, Meslin et al., 2007a). For example 
overexpression of ectopic PrP promotes proliferation of gastric cancer cells 
(SGC7901 and AGS) (Liang et al., 2007). Using antibodies to nullify the 
effect of PrP, McEwan et al. found that PrP promoted proliferation in colon 
cell line (HCT116) (McEwan et al., 2009). When we sought to examine the 
involvement of PrP in the proliferation of breast cancer cells, our BrdU assay 
revealed that the proliferation rate of low PrP expressing breast cancer cell 
lines are markedly increased compared with the normal breast cell line 
MCF10A. This suggests that deficient endogenous PrP expression in breast 
cancer cells could aggravate their growth. However, different genetic 
environment between the normal breast cell line (non-cancer environment) and 
breast cancer cell lines (cancer environment) might contribute to the 
observation instead of the difference in PrP levels. To show the differential 
effects of PrP expression on cell proliferation, PRNP gene was stably 
transfected into MCF7 cells and we demonstrated that the PrP transfected 
MCF7 resulted in a marked reduction in the proliferation rate. This result is 
opposite in trend to other studies such as that in the study on gastric cancer cell 
lines, where researchers showed that PrP is overexpressed in gastric cancer 
tissues (Liang et al., 2006b) as well as in multi-drug-resistant gastric cancer 
cell lines (Zhao et al., 2002). Overexpression of PrP was found in gastric 
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cancers and it correlated with histopathological differentiation parameters 
(Liang et al., 2006a) and also promoted proliferation and tumour progression 
(Liang et al., 2007). These studies indicated that PrP plays a role in promoting 
proliferation and progression in gastric cancer cells. An immediate response to 
why our results differed from these studies could simply be differences in the  
role played by PrP in different cancer cells. However, closer scrutiny of our 
results show a trend of increasing expression of PrP correlating with 
increasing metastasis profile of the breast cancer cells, particularly when 
MDA-MB-231 is compared to MCF7 as shown in Fig. 21A (modified from 
Fig. 10, for comparison with McEwan’s results in Fig. 21B). Our results 
corroborated with that of McEwan et al. who used ELISA assay to detect PrP. 
There, they found that PrP expression correlated with invasiveness and 
malignancies in breast cancer cell lines, reflecting differences in tumour grade 
and metastatic potential as shown in Fig. 21B. (McEwan et al., 2009). Based 
on this result, it might be tempting to look further into the role of PrP in the 
cancer cell lines though it may not be clinically relevant when compared to 
normal cells. This is because in order to understand how cancer works, it is 


















Figure 21: PrP correlates with invasiveness/malignancy of the breast 
cancer cell lines (A) Western blots results – modified from Fig 10. Results 
shown were average ± S.E.M. of 3 experiments. One-way ANOVA. * denotes 
p-value < 0.05. (B) ELISA results of PrP level correlating with aggressiveness 
of breast cancer cell lines (McEwan et al., 2009). 
 
Another plausible reason for the apparent contradictory results could lie in a 
difference in the PrP form between our study versus that of other groups. 
However, this remains to be verified experimentally. What we gathered was 
that Li et al. has discovered that human pancreatic ductal adenocarcinoma cell 
lines (n=7) have upregulated expression of PrP, with islet cells of the normal 
pancreas expressing PrP. More importantly, they further demonstrated that 
only pro-PrP, the immature form of PrP, was detected in human pancreatic 
ductal adenocarcinoma cells, with the GPI anchor peptide signal sequence 
retained. Pro-PrP contains filamin A binding motif and binds to filamin A, a 
scaffolding protein and an integrator of cell mechanics and signalling. Binding 
of pro-PrP to filamin A disrupts the normal function of filamin A, which Li et 
al. hypothesized is likely responsible for the growth advantage of human 
pancreatic ductal adenocarcinoma cell lines (Li et al., 2009a). In other words, 





prognosis in pancreatic cancer. This is corroborated by Xin W, et al. reporting 
that pro-PrP and mature PrP have different biological functions (Xin W., et al. 
2013). It is understood that the interaction between pro-PrP and filamin A does 
not occur in all tumour cells — human neuroblastoma cell lines do not express 
PrP nor filamin A. While other cancer cell lines such as melanoma and human 
hepatocarcinoma cell lines express both proteins (Li et al., 2010, Li et al., 
2009a), it is still unknown (1) why some cancer cells express pro-PrP and 
filamin A while others do not, and (2) whether breast cancer cells exhibit both 
pro-PrP and filamin A. It is thus paramount that subsequent work first identify 
the form of PrP in order to provide relevant insight into the mechanisms where 
it modulates tumour cell biology. 
 
Also, polymorphism in codon 129 (M129V) of the PrP gene, PRNP, is 
associated with neurodegenerative disease development and severity. There is 
however, not much information available regarding its role in cancer incidence 
and disease progression. Antonacopoulou et al. investigated retrospectively the 
potential role of M129V in 110 patients with colorectal cancer and 124 healthy 
donors by genotyping the M129V single nucleotide polymorphism via real 
time polymerase chain reaction. They found that M129V is not a risk factor 
for colorectal cancer, as the results between patients and healthy controls were 
similar (Antonacopoulou et al., 2010). Nevertheless, the role of M129V in 
breast cancer and other cancers remains yet unknown. Consequently, it would 
be interesting to investigate if M129V is a risk factor for breast cancer, and if 
so, how much of a role it might play in proliferation vis-à-vis the difference 
between our results and that of others. 
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We also hypothesized that PrP level differences between the normal and breast 
cancer have correlation with signalling pathways that are involved in 
proliferation, i.e. p53 and/or Akt pathway, and that these interactions 
contribute to the distinct metabolic differences and associations with PrP. It 
has been demonstrated that PI3K signal is an important downstream effector 
of PrP (Diarra-Mehrpour et al., 2004, Krebs et al., 2006, Vassallo et al., 2005). 
In addition, using a two-site chemiluminescence-linked immunosorbent assay 
to measure primary human breast cancer tissue, Cicenas et al. found that Akt 
activation which requires phosphorylation of both thr308 and ser473, is 
associated with tumour proliferation and poor prognostic outcome (Cicenas et 
al., 2005). Intriguingly, overexpression of PrP decreased the phosphorylated 
Akt expression particularly at ser473 proposing a possible fundamental role in 
slowing down proliferation rate in breast cancer cells. Our results contradicted 
with Liang et al. who showed that PrP increased proliferation of gastric cancer 
cell, SGC7901 (Liang et al., 2007), and induced multi-drug resistance in the 
gastric cancer via activation of the PI3K/Akt pathway (Liang et al., 2009). It 
was reported that the use of cancer cell lines may have limitations in 
investigating resistance to chemotherapy drugs and consequently, results from 
such models should be viewed circumspectly. (Phillips, C. 2011).  
 
In the study of Liang et al., the gastric cancer cells were subjected to selection 
pressure via increasing adriamycin, a chemotherapy drug, stepwise to generate 
adriamycin-resistant gastric cancer cell line. This selection pressure could 
have altered the physiological functions of the cells and would perhaps not be 
able to accurately represent how tumours behave in the body. Similarly, some 
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genes involved in the PI3K/Akt pathway that are differentially expressed were 
found to be overexpressed in MCF7 breast cancer cell line with a 17-fold 
upregulation of PrP (Diarra-Mehrpour et al., 2004). Yet, such findings should 
be interpreted with caution as the MCF7 breast cancer cell lines used in the 
study were induced to become TNF-α resistant cells from the parent TNF-
sensitive MCF7 cell lines. Hence, it remains questionable whether the 
modulation of the genes involved in the PI3K/Akt pathway is due to PrP itself, 
or in actual fact, arises from TNF-α after the MCF7 cells were induced into 
becoming TNF-α resistant cells.  
 
 In our study, PrP expression was not associated with p53 expression in the 
breast cancer tissue model. Conversely, p53 expression was markedly 
increased in the breast cancer cell line SK-BR-3 (Kovach et al., 1991) and 
MDA-MB-231 (Olivier et al., 2002) compared with MCF10A. No difference 
was observed in the MCF7 cells. Overexpressing PrP in MCF7 cell lines 
showed no association with p53 expression, this result being in line with our 
breast cancer tissue model. Literature review on the breast cancer cell lines 
showed that SK-BR-3 and MDA-MB-231 express mutated p53 while MCF7 
(Lu et al., 2001) and normal breast cell MCF10A (Merlo et al., 1995) express 
wild-type p53. PrP was shown in studies to be associated with p53 to confer 
cell survival (Kim et al., 2004, Paitel et al., 2002) and p53 was recently 
discovered to regulate metabolic activity by preventing further escalation of 
the Warburg effect through enhancing entry of more pyruvate into the citrate 
cycle (Contractor and Harris, 2012). Therefore it is perhaps premature to 
conclude that PrP expression does not associate with p53 based on our breast 
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tissue and overexpression model system. Could low aberrant expression of PrP 
in SK-BR-3 and MDA-MB-231 be associated with high mutated p53 
expression resulting in a more metastatic breast cancer possibly via 
modulating the metabolic pathway? This question remains to be answered by 
future studies. 
 
As tissue sample sizes are insufficient to fully evaluate the normal and breast 
cancer tissue metabolic characteristics, we addressed this limitation by 
combining our tissue-based observations with current established in vitro 
models to confirm the pathway changes as well as to study the metabolomics 
data which is not possible with clinical samples. While we were unable to 
measure all metabolites, we focused our study on lactate production as it is the 
final by-product and is significantly increased in cells exhibiting Warburg 
effect. Our results demonstrated that the expression of PrP was negatively 
associated with lactate production as shown in the breast cancer cell lines 
study and PrP over-expressing MCF7 cells. An implication of this is the 
possibility that a link may exist between PrP and Warburg effect. LDH-A 
activity in the breast cancer cell lines was markedly increased while the 
pyruvate level was statistically significantly lower, particularly in the SK-BR-
3 and MCF7 cell lines. Both results lend support to increased lactate 
production in low aberrant PrP expression in breast cancer cells. The 
association was however not observed in breast cancer cell line MDA-MB-231. 
Perhaps PrP has other roles apart from influencing lactate production 














Figure 22: Picture showing different lactate production in normal and 












In normal situation, 
some pyruvate will 
be converted into 
lactate via LDH-A 
In tissue becomes 
cancerous, most  
pyruvate will be 
converted into 
lactate via LDH-A 
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It is also noteworthy that one other group has shown that LDH-A is 
upregulated after PrP is induced into mouse neuronal PrP deficient cells 
(Ramljak et al., 2008). The metabolic phenotype of PrP may have a complex 
interplay between species and cell type which might explain the difference we 
observed. Our findings, while preliminary, suggest that PrP modulates cancer 
metabolism and is likely to be linked to the Warburg effect. 
 
As mentioned in the introduction, the function of Akt is pleotropic. Akt plays a 
role in the regulation of glucose uptake into insulin responsive tissues by 
translocating GLUT4 from vesicular intracellular compartments to the plasma 
membrane. The role of Akt in this process was demonstrated using 
constitutively active Akt mutants that induce GLUT4 translocation in the 
absence of insulin (Kohn et al., 1996). In addition, depletion of Akt using 
small interfering RNA-mediated knockdown results in decreased insulin-
stimulated glucose uptake (Welsh et al., 2005). We therefore questioned if PrP 
modulated phosphorylated Akt (ser473) to alter glucose transporter to carry 
out their function in proliferation as well as cell metabolism as shown in Fig 
23. 

















Figure 23: Schematic overview of the role of PrP in breast cancer 
metabolism in the study model.    
 
Li et al. (2011) observed that by abolishing PrP in colorectal cancer DLD-1 
cells, GLUT1 gene was markedly altered using array hybridization analysis 
(Li et al., 2011). Therefore, using our overexpression model we sought to 
investigate the function of PrP and its association with glucose transporters. 
Interestingly, PrP-overexpressing MCF7 cells demonstrated marked reduction 
in GLUT4 expression. Notably GLUT4, the insulin regulated glucose 
transporter, is found in various human malignant breast tissue and cell lines 
including MCF7 (Birnbaum, 1989, Brown and Wahl, 1993). Therefore, it 
appears possible that PrP downregulates breast cancer proliferation via 
preferentially inhibiting phosphorylation of Akt at ser473, which might lead to 
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Overall, our findings are surprising as it is in opposition to observations by 
other groups, where they demonstrated that PrP is associated with proliferation, 
and survival of cells (Liang et al., 2007), (Morel et al., 2008), (Diarra-
Mehrpour et al., 2004). Several factors had been discussed as possibly 
contributing to this apparent discrepancy in our case and it is intriguing to note 
that Yu et al. found it necessary to make the following comment:  
“PrP knockdown in MDA-MB-435 cells may alter multiple 
signalling pathways. Depending on which pathway is involved in the 
cellular response to a particular cytotoxic stimulus, PrP knockdown 
may have pro- or anti-cell death effect.” (Yu et al., 2012). 
This shows that the physiological role of PrP in relation to cancer progression 
is far from being settled unambiguously. Thus, there is a possibility that the 
role of PrP could be even more complex across cell lines. This could arise 
from genetic deviations within cell lines. Jones et al. showed that there are 3 
strains of MCF7 cells using genomic hydridisation and their proliferation rates 
differ (Jones et al., 2000). The diversity of factors that affect the proliferation 
in MCF7 cells suggest that the previously described proliferation effect by PrP 
(Diarra-Mehrpour et al., 2004) may be specific for a particular strain variant 
and may not be generally reproducible in other variants, much less other cell 
types. In addition, their use of MCF7 cells with ablated p53 that do not 
respond to Fas ligand (Diarra-Mehrpour et al., 2004) could cause results to 
differ as it might affect the proliferation rate as well as the metabolic activity 




We observed that our transfected cell lines yielded different results, i.e. 
significant levels for phosphorylated Akt (ser473) and GLUT4 were only 
achieved in PrP overexpressed MCF7 clone B and not in clone A. One 
possible cause could be our use of a transfection system that is not site-
directed. Random insertion of PrP may give rise to variability in the results. 
Hence, a better option would be to use a site directed insertion of the PrP 
construct into the MCF7, which would eliminate this potential confounder.  
 
All in all, PrP might be playing a role in modulating the progression of breast 
cancer, as we showed that low aberrant PrP expression in breast cancer cells 
led to marked proliferation rate. This effect could be due to the up-regulation 
of phosphorylated Akt ser473 causing the increased expression of GLUT4 











Figure 24: Schematic overview of the role of PrP in cancer metabolism in 
breast cancer cells. PrP expression reduces cellular proliferation and 










The key strength of our study lies in our in vitro work supporting the results 
based on the clinical samples. PrP expression in both normal breast tissue and 
the normal cell line MCF10A, have higher expression compared with their 
cancer counterparts. Overexpression of PrP in MCF7 cell line demonstrated 
that PrP expression dampens proliferation and reduces lactate production. The 
possible pathway could be via reduction of phosphorylated Akt (ser473), 
leading to lowered GLUT4 as shown in Fig 24. Taken together, the apparent 
physiological role of PrP observed from this study seems to portray PrP as 
having cancer protecting effect. 
 
However, we are still at the initial stages of understanding the complex 
interplay between PrP, cancer biology and metabolism. Investigating the 
underlying mechanisms that link to the physiological roles of PrP remain an 
important work for understanding its functions in carcinogenesis and also in 
prion diseases. Gene-silencing studies, such as that by Yu et al., in cell lines 
highly expressing PrP is a relevant next step. Subsequently, it would be 
desirable to extend the findings of this study to in vivo models, for example by 
using nude mouse bearing human MCF7 xenograph to investigate if tumour 
growth is inhibited by treatment with PrP. This will be essential as it can help 
to uncover the molecular mechanisms of the role ascribed to PrP, and how it 
might play a role in subverting carcinogenesis and becoming a possible 
targeted cancer therapy.  
 
We showed that overexpression of PrP in our study model affects Akt 
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phosphorylation (ser473) and more importantly it decreases GLUT4 
expression, which is an insulin-linked glucose transporter. Hence, studying the 
association of PrP and the insulin pathway with cancer might shed new light in 
finding a potential pathway where PrP mitigates cancer progression. 
 
In addition, as we have shown that overexpression of PrP is correlated with 
lowered lactate production, suggesting that it may have a possible role in 
mitigating the Warburg effect in cancer cells. Further investigations into the 
oxygen and glucose consumptions are indispensable to verify the phenotype of 
the Warburg effect in our model.  
 
Hence, the apparent physiological role of PrP observed from our study seems 
to portray a close connection between PrP and cancer regression. It is still 
premature to suggest that overexpressing PrP in cancer cells could provide a 
new therapeutic strategy. Nonetheless, it provides an important insight 
especially in its association with GLUT4 expression. Hence, we speculate that 
PrP might be involved in the insulin pathway. This role might be applied in the 
insulin potentiation therapy against cancer.  
 
Based on our findings, it can be seen that PrP may have numerous important 
implications for carcinogenesis. Although the exact mechanisms involved in 
proliferation and metabolism remains to be elucidated definitively, the results 
here provide a stimulus for further studies on the role of PrP in cancer biology 
not just in proliferation and metabolism, but also in other hallmarks for cancer 
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